PURPOSE: @entity1069 ( @entity1069 ) may improve the detection of @entity263 in @entity1 presenting for prostate biopsy. We report clinical outcomes of 12-core systematic biopsy and @entity1069 in @entity1 who presented for primary biopsy and further describe pathological characteristics of @entity5 detected by systematic biopsy and not by @entity1069 . MATERIALS AND METHODS: Clinical outcomes of 452 consecutive @entity1 who underwent prebiopsy multiparametric magnetic resonance imaging followed by @entity1069 and systematic biopsy at our institution between June 2012 and June 2015 were captured in an institutional review board approved database. Clinical characteristics, biopsy results and magnetic resonance imaging suspicion scores were queried from the database. RESULTS: @entity263 was detected in 207 of 382 @entity1 (54.2%) with a mean     SD age of 64    8.5 years and mean    SEM prostate specific antigen 6.8    0.3  ng/ml who met study inclusion criteria. The @entity5 detection rate of systematic biopsy and @entity1069 was 49.2% and 43.5%, respectively (p = 0.006). @entity1069 detected more Gleason score 7 or greater @entity5 than systematic biopsy (117 of 132 or 88.6% vs 102 of 132 or 77.3%, p = 0.037). Of 41 @entity5 detected by systematic biopsy but not by @entity1069 34 (82.9%) demonstrated @entity19355 , and 26 (63.4%) and 34 (82.9%) were clinically insignificant by Epstein criteria and a UCSF CAPRA (University of California-San Francisco-Cancer of the Prostate Risk Assessment) score of 2 or less, respectively. CONCLUSIONS: In @entity1 presenting for primary prostate biopsy @entity1069 detects more high grade @entity5 than systematic biopsy. Most @entity5 detected by systematic biopsy and not by @entity1069 are at clinically low risk. Prebiopsy magnetic resonance imaging followed by @entity1069 decreases the detection of @entity5 while significantly improving the detection and risk stratification of high grade disease.

Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy in a Consecutive Cohort of XXXX with No Previous Biopsy: Reduction of Over Detection through Improved Risk Stratification.

@entity1 :: ('9606', 'Species') :: ['men'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer', 'Prostate cancer'] @entity1069 :: ('MESH:D053448', 'Disease') :: ['magnetic resonance imaging-ultrasound fusion targeted prostate biopsy', 'MRF-TB'] @entity5 :: ('MESH:D009369', 'Disease') :: ['low risk cancers', 'cancers', 'cancer'] @entity19355 :: ('MESH:D005077', 'Disease') :: ['Gleason 6  disease']
@entity1 :: (9606,Species) :: ['Men']
